A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

University of Rochester Medical Center, Rochester

Asheville Cardiology Associates, PA, Asheville

University of Florida Health Science Center, Jacksonville

Miami International Cardiology Consultants, Miami Beach

Mediquest Research Group, Ocala

Northwestern Memorial Hospital, Elyria

Michigan Heart, Ypsilanti

Borgess Medical Center, Kalamazoo

Iowa Heart Center, Des Moines

Minneapolis Heart Institute Foundation, Minneapolis

Midwest Heart Research Foundation, Lombard

St. Louis University, St Louis

Alton Ochsner Medical Foundation, New Orleans

Oklahoma Foundation for Cardiovascular Research, Oklahoma City

IRCI Institute for Research in Cardiovascular Interventions at The Methodist DeBakey Heart Center, Houston

Austin Heart, Austin

University of Utah, Salt Lake City

St. Luke's Medical Center, Phoenix

University of Arizona Sarver Heart Center, Tucson

Nevada Cardiology Associates, Las Vegas

La Mesa Cardiac Center, La Mesa

Foundation for Cardiovascular Medicine, La Jolla

Clinical Research Center of California, San Diego

Veterans Affairs Medical Center, San Diego

Cardiovascular Associates of the Peninsula, Burlingame

Brigham and Women's Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Baystate Medical Center, Springfield

University of Texas Health Science Center, San Antonio